The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles.
Journal
Pharmacogenomics
ISSN: 1744-8042
Titre abrégé: Pharmacogenomics
Pays: England
ID NLM: 100897350
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
entrez:
25
5
2019
pubmed:
28
5
2019
medline:
14
4
2020
Statut:
ppublish
Résumé
HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and circRNAs in the cell-lines HB4a and C5.2, where the latter is a HER2-overexpressing clone of the former, and also from two different populations of their secreted extracellular vesicles. Whereas circRNA-levels were stable, we found at least 16 miRNAs apparently modulated by HER2-expression. The miR223-3p, miR-421 and miR-21-5p were validated in an independent cohort of 431 breast cancer patients from The Cancer Genome Atlas (TCGA). The consistent modulation of these molecules and their possible involvement in the HER2-axis makes them promising new targets to overcome HER2-activation.
Identifiants
pubmed: 31124410
doi: 10.2217/pgs-2018-0182
doi:
Substances chimiques
MIRN21 microRNA, human
0
MIRN421 microRNA, human
0
MicroRNAs
0
RNA, Circular
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM